{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:20:47Z","timestamp":1790626847793,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":1344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Ministry of Health & Welfare, Republic of Korea","award":["HI14C2223"],"award-info":[{"award-number":["HI14C2223"]}]},{"DOI":"10.13039\/100006436","name":"Celgene and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Ministry of Health & Welfare, Republic of Korea","award":["HI14C2223"],"award-info":[{"award-number":["HI14C2223"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1093\/annonc\/mdv596","type":"journal-article","created":{"date-parts":[[2015,12,10]],"date-time":"2015-12-10T03:56:26Z","timestamp":1449719786000},"page":"508-513","source":"Crossref","is-referenced-by-count":59,"title":["Epstein\u2013Barr virus reactivation in extranodal natural killer\/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin"],"prefix":"10.1016","volume":"27","author":[{"given":"S.J.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.S.","family":"Ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.H.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv596_bb0010","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv596_bb0015","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv596_bb0020","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv596_bb0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1011144911781","article-title":"CHOP followed by involved field radiation: is it optimal for localized nasal natural killer\/T-cell lymphoma?","volume":"12","author":"Kim","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv596_bb0030","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2008-10-185256","article-title":"Clinical differences between nasal and extranasal natural killer\/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project","volume":"113","author":"Au","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv596_bb0035","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv596_bb0040","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1200\/JCO.2009.23.8592","article-title":"Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK\/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study","volume":"27","author":"Kim","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv596_bb0045","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv596_bb0050","doi-asserted-by":"crossref","first-page":"9279","DOI":"10.1128\/JVI.00982-07","article-title":"De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists","volume":"81","author":"Ye","year":"2007","journal-title":"J Virol"},{"key":"10.1093\/annonc\/mdv596_bb0055","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1128\/JVI.00116-08","article-title":"Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors","volume":"82","author":"Countryman","year":"2008","journal-title":"J Virol"},{"key":"10.1093\/annonc\/mdv596_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5045\/br.2013.48.3.171","article-title":"Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party","volume":"48","author":"Suh","year":"2013","journal-title":"Blood Res"},{"key":"10.1093\/annonc\/mdv596_bb0065","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv596_bb0070","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1128\/JCM.05593-11","article-title":"Comparison of commercial extraction systems and PCR assays for quantification of Epstein-Barr virus DNA load in whole blood","volume":"50","author":"Germi","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"Pt 9","key":"10.1093\/annonc\/mdv596_bb0075","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1099\/0022-1317-66-9-1931","article-title":"Chromatin structure of Epstein-Barr virus","volume":"66","author":"Dyson","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1093\/annonc\/mdv596_bb0080","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/JVI.01602-10","article-title":"Interplay between PKCdelta and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation","volume":"85","author":"Tsai","year":"2011","journal-title":"J Virol"},{"key":"10.1093\/annonc\/mdv596_bb0085","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/bcmd.1998.0178","article-title":"Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma","volume":"24","author":"Mentzer","year":"1998","journal-title":"Blood Cells Mol Dis"},{"key":"10.1093\/annonc\/mdv596_bb0090","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv596_bb0095","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/leu.2013.212","article-title":"Quantification of circulating Epstein-Barr virus DNA in NK\/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance","volume":"28","author":"Kwong","year":"2014","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdv596_bb0100","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3324\/haematol.2009.008607","article-title":"Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report","volume":"94","author":"Ritchie","year":"2009","journal-title":"Haematologica"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419355930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419355930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/3\/508\/6676466\/mdv596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:50:14Z","timestamp":1624693814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419355930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0923753419355930"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv596","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}